Examkin

Soru

Zorluk: ZorPediatric Genetic and Metabolic Disorders

A 12-month-old boy is brought to the pediatric genetics clinic for evaluation of global developmental delay and recurrent otitis media. His parents report that he sat independently at 9 months but is not yet crawling or pulling to stand. Vital signs are within normal limits. Physical examination reveals macrocephaly, a prominent forehead, thickened facial features, and a flattened nasal bridge. Ophthalmologic examination shows bilateral corneal clouding. Abdominal examination demonstrates a firm liver edge palpable 4 cm below the right costal margin and a palpable spleen tip. Initial skeletal radiography shows anterior beaking of the lumbar vertebrae and thickened, shortened diaphyses (dysostosis multiplex). The physician suspects a severe metabolic disorder.

Arrange the following diagnostic and management steps in the most appropriate chronological sequence for this patient, from initial evaluation to definitive long-term therapy.

  1. 1Quantitative analysis of urinary glycosaminoglycans
  2. 2Measurement of leukocyte alpha-L-iduronidase enzyme activity
  3. 3Molecular sequencing of the IDUA gene
  4. 4Initiation of intravenous enzyme replacement therapy (laronidase)
  5. 5Hematopoietic stem cell transplantation (HSCT)

Cevap

The correct sequence is: Quantitative analysis of urinary glycosaminoglycans -> Measurement of leukocyte alpha-L-iduronidase enzyme activity -> Molecular sequencing of the IDUA gene -> Initiation of intravenous enzyme replacement therapy -> Hematopoietic stem cell transplantation.
The evaluation of a suspected mucopolysaccharidosis (such as Hurler syndrome) follows a strict chronological pathway. Initial screening involves measuring urinary glycosaminoglycans (GAGs), which accumulate due to defective lysosomal degradation. Elevated GAGs prompt the definitive diagnostic step: measuring specific enzyme activity (alpha-L-iduronidase in leukocytes). Once the biochemical diagnosis is confirmed, molecular sequencing of the IDUA gene is performed to establish genotype-phenotype correlation and guide genetic counseling. Therapeutically, because hematopoietic stem cell transplantation (HSCT) is the only modality that can prevent progressive central nervous system deterioration (as it allows donor-derived macrophages to cross the blood-brain barrier and secrete enzyme), it is the ultimate goal. However, finding a donor requires time; therefore, intravenous enzyme replacement therapy (laronidase) is initiated immediately upon diagnosis as a bridge to treat severe somatic complications (e.g., respiratory compromise, hepatosplenomegaly) while preparing for transplant.

Adım Adım Çözüm

1
Identify the clinical syndrome based on the vignette.
The patient exhibits classic features of Mucopolysaccharidosis Type I (Hurler syndrome), including developmental delay, coarse facial features, corneal clouding, hepatosplenomegaly, and dysostosis multiplex.
Recognizing this constellation of findings directs the step-wise diagnostic workup for lysosomal storage diseases.
2
Determine the initial diagnostic screening test.
Quantitative analysis of urinary glycosaminoglycans (GAGs) is selected first.
Urinary GAG analysis is the most appropriate, rapid, and cost-effective initial biochemical screen for suspected mucopolysaccharidoses.
3
Determine the definitive confirmatory diagnostic test.
Measurement of leukocyte alpha-L-iduronidase enzyme activity is selected next.
Once GAGs are elevated, specific enzyme activity assay in leukocytes or fibroblasts is the gold standard for definitive diagnosis.
4
Identify the role of subsequent genetic testing.
Molecular sequencing of the IDUA gene follows biochemical diagnosis.
Genotyping is required for predicting phenotypic severity, identifying carrier status in relatives, and planning future prenatal diagnostics.
5
Order the chronological therapeutic interventions.
Enzyme replacement therapy (ERT) is initiated, followed by hematopoietic stem cell transplantation (HSCT).
ERT is started immediately to bridge the patient and treat somatic symptoms, while HSCT is pursued as the definitive long-term treatment because it can preserve neurocognitive function (ERT cannot cross the blood-brain barrier).

Anahtar Kavram

Chronological evaluation and management of Mucopolysaccharidosis Type I (Hurler syndrome)
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Pediatric Genetic and Metabolic Disorders

Bu konudan daha fazla soru